{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-009629","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.468426+00:00","generated_at":"2026-06-17T10:22:36.056261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalo Therapeutics reports 2022 net loss of $41.7M; Phase 2 PEAK trial enrollment complete","bullets":["Net loss of $41.7M for 2022, improved from $84.4M in 2021; net loss per share $4.43.","Total revenues $18.1M, up from $5.4M, driven by $14.5M upfront from AVTX-007 out-license.","Cash and equivalents $13.2M at Dec 31, 2022; raised $13.7M net in Feb 2023 public offering.","Completed enrollment of Phase 2 PEAK trial of AVTX-002 in non-eosinophilic asthma (91 patients); topline data expected Q2 2023.","Identified lead molecule for AVTX-008 (BTLA agonist); target IND submission in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-009629","json":"https://secwatch.observer/filing/0001628280-23-009629.json","markdown":"https://secwatch.observer/filing/0001628280-23-009629.md","text":"https://secwatch.observer/filing/0001628280-23-009629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023009629/0001628280-23-009629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023009629/avtx-20230329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:22:36.056261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8fdc6a232baf5a4722677bdc166cbf89607b970d","claim":"Avalo Therapeutics, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 29, 2023, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023009629/0001628280-23-009629-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}